安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Agios
Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs Our mature and unique understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together
- Agios Pharmaceuticals - Wikipedia
Agios Pharmaceuticals Inc is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias [5]
- Agios Reports First Quarter 2026 Financial Results and Provides . . .
Agios will host a conference call and live webcast today at 8:00 a m ET to discuss the company’s first quarter 2026 financial results and recent business highlights
- Agios Pharmaceuticals (AGIO) Stock Price Overview
A detailed overview of Agios Pharmaceuticals, Inc (AGIO) stock, including real-time price, chart, key statistics, news, and more
- Agios Pharmaceuticals (AGIO) Stock Price, News Analysis
Agios markets its therapies directly in the United States and partners with global pharmaceutical companies for commercialization in Europe and other regions Agios went public in 2013 and has maintained its headquarters and core research operations in Cambridge
- Agios Pharmaceuticals, Inc. (AGIO) - Yahoo Finance
Find the latest Agios Pharmaceuticals, Inc (AGIO) stock quote, history, news and other vital information to help you with your stock trading and investing
- AGIO Stock Price Quote | Morningstar
See the latest Agios Pharmaceuticals Inc stock price (AGIO:XNAS), related news, valuation, dividends and more to help you make your investing decisions
- Agios Pharmaceuticals (AGIO) Heavy EPS Loss Tests Growth‑Led Bullish . . .
Agios Pharmaceuticals (AGIO) has opened Q1 2026 earnings season with a recent run of quarterly results that show total revenue of $19 97 million in Q4 2025 and a basic EPS loss of $1 85, alongside trailing twelve month revenue of $54 03 million and a basic EPS loss of $7 12 Over the past six reported quarters, the company has seen quarterly revenue move between $8 73 million and $19 97
|
|
|